EA202190623A1 - Оптически активное азабициклическое производное - Google Patents

Оптически активное азабициклическое производное

Info

Publication number
EA202190623A1
EA202190623A1 EA202190623A EA202190623A EA202190623A1 EA 202190623 A1 EA202190623 A1 EA 202190623A1 EA 202190623 A EA202190623 A EA 202190623A EA 202190623 A EA202190623 A EA 202190623A EA 202190623 A1 EA202190623 A1 EA 202190623A1
Authority
EA
Eurasian Patent Office
Prior art keywords
optically active
azabicyclic derivative
mll
derivative
active azabicyclic
Prior art date
Application number
EA202190623A
Other languages
English (en)
Inventor
Сейдзи Камиока
Хитоси Бан
Наоаки Симада
Ватару Хиросе
Акихико Аракава
Казуто Ямазаки
Кендзиро Хира
Original Assignee
Сумитомо Дайниппон Фарма Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сумитомо Дайниппон Фарма Ко., Лтд. filed Critical Сумитомо Дайниппон Фарма Ко., Лтд.
Publication of EA202190623A1 publication Critical patent/EA202190623A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

Настоящее изобретение относится к соединению формулы (1a), где p представляет собой 1 или 2, R1-R4 представляют собой атом водорода или другие подобные группы, и a-d представляют собой 1 или 2, или его фармацевтически приемлемой соли, которое обладает противоопухолевым эффектом, обусловленным ингибированием связывания между слитым белком MLL, который слит с AF4, AF9 или другими подобными белками и который представляет собой типичный ген-партнер по слиянию, вызывающий MLL лейкоз, и менином.
EA202190623A 2018-08-27 2019-08-26 Оптически активное азабициклическое производное EA202190623A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018158315 2018-08-27
PCT/JP2019/033234 WO2020045334A1 (ja) 2018-08-27 2019-08-26 光学活性なアザビシクロ環誘導体

Publications (1)

Publication Number Publication Date
EA202190623A1 true EA202190623A1 (ru) 2021-05-21

Family

ID=69644540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190623A EA202190623A1 (ru) 2018-08-27 2019-08-26 Оптически активное азабициклическое производное

Country Status (14)

Country Link
US (3) US11369605B2 (ru)
EP (1) EP3845533A4 (ru)
JP (3) JP6671574B1 (ru)
KR (1) KR20210049136A (ru)
CN (1) CN112585140B (ru)
AU (1) AU2019327006B2 (ru)
BR (1) BR112021002090A8 (ru)
CA (1) CA3107743A1 (ru)
EA (1) EA202190623A1 (ru)
MX (1) MX2021002424A (ru)
PH (1) PH12021550229A1 (ru)
SG (1) SG11202101085PA (ru)
TW (1) TWI815954B (ru)
WO (1) WO2020045334A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210198283A1 (en) * 2018-08-08 2021-07-01 Sumitomo Dainippon Pharma Co., Ltd. Optically active bridged piperidine derivative
KR20210049136A (ko) * 2018-08-27 2021-05-04 다이니뽄 스미토모 세이야쿠 가부시키가이샤 광학 활성인 아자비시클로환 유도체
US20220380365A1 (en) * 2019-09-27 2022-12-01 Sumitomo Dainippon Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
JP7454520B2 (ja) 2020-02-26 2024-03-22 住友ファーマ株式会社 光学活性なアザビシクロ環誘導体からなる医薬
CR20230314A (es) 2020-12-17 2023-08-18 Astrazeneca Ab N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas
JP2024518425A (ja) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． 置換スピロ誘導体
EP4334310A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
WO2023098876A1 (en) * 2021-12-03 2023-06-08 Bionova Pharmaceuticals (Shanghai) Limited Carbonyl substituted diazaspiro compounds and its use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
AR039208A1 (es) 2002-04-03 2005-02-09 Syngenta Participations Ag Compuestos de fenil- y piridilalquinos, composicion herbicida que los contiene, procedimiento de preparacion de aquellos y procedimiento para combatir el crecimiento de plantas indeseadas
TW200528440A (en) 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
TW200902010A (en) 2007-01-26 2009-01-16 Smithkline Beecham Corp Anthranilamide inhibitors of aurora kinase
US20090281114A1 (en) 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
AU2015259173B2 (en) 2014-05-13 2019-09-05 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
JP2018538330A (ja) 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
CA3024180A1 (en) * 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
CA3033020A1 (en) * 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of menin-mll interaction
WO2018050686A1 (en) 2016-09-14 2018-03-22 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction
WO2018053267A1 (en) * 2016-09-16 2018-03-22 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
EP3562823B1 (en) * 2016-12-28 2023-02-08 Promega Corporation Functionalized nanoluc inhibitors
JP7239562B2 (ja) 2018-03-30 2023-03-14 住友ファーマ株式会社 光学活性な架橋型環状２級アミン誘導体
US10815241B2 (en) * 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
KR20210049136A (ko) * 2018-08-27 2021-05-04 다이니뽄 스미토모 세이야쿠 가부시키가이샤 광학 활성인 아자비시클로환 유도체

Also Published As

Publication number Publication date
CN112585140B (zh) 2023-07-04
JP6671574B1 (ja) 2020-03-25
JPWO2020045334A1 (ja) 2020-09-03
JP2020105191A (ja) 2020-07-09
US20210338668A1 (en) 2021-11-04
JP2023134729A (ja) 2023-09-27
AU2019327006A1 (en) 2021-03-04
CN112585140A (zh) 2021-03-30
KR20210049136A (ko) 2021-05-04
PH12021550229A1 (en) 2021-10-11
US20240148727A1 (en) 2024-05-09
EP3845533A1 (en) 2021-07-07
TWI815954B (zh) 2023-09-21
CA3107743A1 (en) 2020-03-05
AU2019327006B2 (en) 2024-02-15
BR112021002090A8 (pt) 2022-12-06
SG11202101085PA (en) 2021-03-30
BR112021002090A2 (pt) 2021-05-04
US11369605B2 (en) 2022-06-28
JP7317749B2 (ja) 2023-07-31
MX2021002424A (es) 2021-04-28
US11911381B2 (en) 2024-02-27
TW202024082A (zh) 2020-07-01
WO2020045334A1 (ja) 2020-03-05
US20220288072A1 (en) 2022-09-15
EP3845533A4 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
EA202190623A1 (ru) Оптически активное азабициклическое производное
WO2020097537A3 (en) Fused ring compounds
MX2021001706A (es) Compuestos de anillo fusionado.
CR20210247A (es) Nuevos compuestos heterocíclicos
EA202091479A1 (ru) Арил- и гетероарилзамещенные индольные соединения
EA202091484A1 (ru) 4-азаиндольные соединения
MX2020009948A (es) Amidas heterocíclicas útiles como moduladores de proteínas.
PH12021500013A1 (en) New heterocyclic compounds as monoacylgylcerol lipase inhibitors
AR114803A1 (es) Compuestos de 4-aminoisoindolin-1,3-diona sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
EA200300942A1 (ru) Производные n-(арилсульфонил)бета-аминокислот, содержащие замещенную аминометильную группу, способ их получения и содержащие их фармацевтические композиции
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
NZ774126A (en) Spd-1 variant - fc fusion proteins
EA202192405A1 (ru) Составы антител против il-36r
CR20220116A (es) Compuestos heterocíclicos
CR20220117A (es) Compuestos heterocíclicos
MX2021002529A (es) Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos.
MX2022000243A (es) Nuevos compuestos heterociclicos.
EA202090653A1 (ru) Циклоолефиновые замещённые гетероароматические соединения и их применение
PH12021551055A1 (en) Klk5 inhibitory peptide
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
MX2021006692A (es) Proceso mejorado para preparar ozanimod.